Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of DNA-sequence-targeting and mRNA-encoded therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 116 full-time employees. The company went IPO on 2021-07-30. The Company’s OMEGA platform has enabled it to identify and validate various DNA-sequence-based epigenomic, zip codes, associated with individual regulatory elements within Insulated Genomic Domains (IGDs). The firm designs and engineers its mRNA therapeutics, which are programmable and modular epigenetic medicines, called omega epigenomic controllers (OECs), to target EpiZips for precision epigenomic control. Its pipeline consists of early-stage programs that span oncology, multigenic diseases including immunology, regenerative medicine, and select monogenic diseases. The Company’s precision epigenomic control delivered by the OMEGA platform has therapeutic applicability and transformational potential, spanning across oncology, multigenic diseases including immunology, regenerative medicine and select monogenic diseases.